BioGenex, a pioneer in automated staining solution provider for cancer diagnostics announces the launch of three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis. The new launch includes:
CD8A: Studies have confirmed that CD8 expression is a recurrent albeit rare phenomenon in patients with CLL and suggests CD8 expression has an adverse prognostic impact. Read more
CD56: CD56 is a phenotypical marker for natural killer cells and many other immune cells, including alpha-beta T cells, gamma delta T cells, dendritic cells and monocytes and can be used to distinguish many tumors such as myeloma, Wilm’s Tumor, neuroblastoma, Ewing’s Sarcoma and many others. Read more
CD163: CD163 can interact and bind with gram-positive and gram-negative bacteria, functioning like a macrophage receptor. Read more
ha-beta T cells, gamma delta T cells, dendritic cells and monocytes and can be used to
BioGenex offers over 400 antibodies for various panels in ready-to-use and concentrated format. Our antibodies are compatible with fully automated staining systems and detection systems for clean and intense staining.